{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:22:02Z","timestamp":1785410522383,"version":"3.56.0"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","award":["66-017-2"],"award-info":[{"award-number":["66-017-2"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]},{"award":["66-017-2"],"award-info":[{"award-number":["66-017-2"]}],"id":[{"id":"https:\/\/ror.org\/0575ycz84","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>We compared the cytokine profiles between two lupus low disease activity state (LLDAS) subgroups\u2014clinically active (CA) and serologically active clinically quiescent (SACQ)\u2014and identified predictors of disease flare. Fifty patients with systemic lupus erythematosus (25 CA, 25 SACQ) who maintained LLDAS for \u22656 months were enrolled and followed for 6 months. Cytokine modules were identified using weighted gene co-expression network analysis, and correlations with clinical traits were assessed. Predictors of flare were assessed using Cox regression. Three cytokine modules were identified. The brown (MCP-1 and IL-8) and turquoise (IFN-\u03b1, IFN-\u03b3, IL-17A, IL-10, IL-12p70, IL-18, IL-23A, and IL-33) modules correlated with mucocutaneous and physician global assessment, respectively. These modules showed a positive, but not significant, correlation with CA. The comparison analysis revealed that IL-6 and IL-8 were higher in CA than in SACQ. Nine patients (18%) flared, six of whom belonged to the CA group. Flares were associated with a lower sustained LLDAS rate (77.8% vs. 34.1%) and higher levels of IL-1\u03b2, IL-6, and IL-33. In multivariable analysis, non-sustained LLDAS (HR 8.73) and IL-6 \u2265 45.1 pg\/mL (HR 10.4) independently predicted a flare. Our study demonstrated that cytokine elevation persists despite LLDAS. Non-sustained LLDAS and elevated IL-6 predict a flare, suggesting that IL-6 may enhance the flare prediction biomarker.<\/jats:p>","DOI":"10.3390\/ijms27093913","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:33:37Z","timestamp":1777376017000},"page":"3913","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct Cytokine Profiles in Lupus Low Disease Activity State Subgroups Identify Patients at Risk for Disease Flare"],"prefix":"10.3390","volume":"27","author":[{"given":"Warot","family":"Piriyasanguanpong","sequence":"first","affiliation":[{"name":"Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonjing","family":"Siripaitoon","sequence":"additional","affiliation":[{"name":"Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1028-3329","authenticated-orcid":false,"given":"Siriporn","family":"Juthong","sequence":"additional","affiliation":[{"name":"Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parichat","family":"Uea-Areewongsa","sequence":"additional","affiliation":[{"name":"Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-3963","authenticated-orcid":false,"given":"Porntip","family":"Intapiboon","sequence":"additional","affiliation":[{"name":"Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: Final recommendations from an international task force","volume":"8","author":"Bertsias","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1111\/1756-185X.70021","article-title":"The 2024 APLAR Consensus on the Management of Lupus Nephritis","volume":"28","author":"Mok","year":"2025","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_4","unstructured":"Sammaritano, L.R., Askanase, A., Bermas, B.L., Dall\u2019Era, M., Duarte-Garc\u00eda, A., Hiraki, L.T., Son, M.B.F., Werth, V.P., Aranow, C., and Barnado, A. (2025). 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Care Res., 1\u201325."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kead159","article-title":"Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist\u2019s judgement?","volume":"63","author":"Tomero","year":"2024","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2016-210382","article-title":"Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus","volume":"76","author":"Mok","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/annrheumdis-2017-211814","article-title":"Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: Data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)","volume":"76","author":"Wojdyla","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13075-019-2029-1","article-title":"Performance of cytokine models in predicting SLE activity","volume":"21","author":"Ruchakorn","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Santana-S\u00e1nchez, P., Ram\u00edrez-P\u00e9rez, A.A., Alberti-Minutti, P., Gaj\u00f3n, J.A., Bonifaz, L.C., S\u00e1nchez-Escobar, N., Legorreta-Haquet, M.V., Ch\u00e1vez-S\u00e1nchez, L., and Ch\u00e1vez-Rueda, A.K. (2025). Cytotoxic Molecules as Potential Biomarkers for Active and Inactive Systemic Lupus Erythematosus. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071559"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3899\/jrheum.2025-0390.PV030","article-title":"Serum Biomarkers and Interferon-Alpha Concentration and Their Correlation to Disease Activity in 62 Estonian Systemic Lupus Erythematosus (Sle) Patients","volume":"52","author":"Meisalu","year":"2025","journal-title":"J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dreveton, L.S., Spencker, J.J., Rincon-Arevalo, H., Aue, A., Osmanodja, B., Wiedemann, A., Szelinski, F., Kr\u00f6nke, G., D\u00f6rner, T., and Schrezenmeier, E. (2025). Soluble checkpoint molecules as predictive biomarker for disease activity and long-term outcome in SLE. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1685275"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard-2023-224795","article-title":"Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-\u03bb1 with Th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of Physician Global Assessment in systemic lupus erythematosus: A systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3899\/jrheum.150040","article-title":"Lack of Interferon and Proinflammatory Cyto\/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus","volume":"42","author":"Steiman","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/09612033221102575","article-title":"Role of interleukin-6 and interferon-\u03b1 in systemic lupus erythematosus: A case-control study and meta-analysis","volume":"31","author":"Pattanaik","year":"2022","journal-title":"Lupus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1801","DOI":"10.6061\/clinics\/2020\/e1801","article-title":"Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: A meta-analysis","volume":"75","author":"Ding","year":"2020","journal-title":"Clinics"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Richter, P., Rezus, C., Burlui, A.M., Schreiner, T.G., and Rezus, E. (2025). Serum Interleukin-6 in Systemic Lupus Erythematosus: Insights into Immune Dysregulation, Disease Activity, and Clinical Manifestations. Cells, 14.","DOI":"10.3390\/cells14191568"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: A prospective, multinational, longitudinal cohort study","volume":"4","author":"Golder","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3899\/jrheum.2023-0900","article-title":"Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients with Newly Diagnosed Versus Established Systemic Lupus Erythematosus","volume":"51","author":"Golder","year":"2024","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","article-title":"The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial","volume":"142","author":"Buyon","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S2665-9913(22)00107-2","article-title":"Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: The PISCOS study","volume":"4","author":"Piga","year":"2022","journal-title":"Lancet Rheumatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3913\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:55:11Z","timestamp":1777377311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/9\/3913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27093913"],"URL":"https:\/\/doi.org\/10.3390\/ijms27093913","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}